Psychotrope And NotChris Armstrong Esther
List of bibliographic references
Number of relevant bibliographic references: 30.Ident. | Authors (with country if any) | Title |
---|---|---|
000005 | Michel Panisset [Canada] ; Jack J. Chen [États-Unis] ; Sean H. Rhyee [États-Unis] ; Jill Conner [États-Unis] ; Julie Mathena [États-Unis] | Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO) |
000044 | James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
000071 | Philip Seeman [Canada] ; Michele Tinazzi [Italie] | Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia |
000094 | Mee-Sook Song [Canada] ; Dmitriy Matveychuk [Canada] ; Erin M. Mackenzie [Canada] ; Maryana Duchcherer [Canada] ; Darrell D. Mousseau [Canada] ; Glen B. Baker [Canada] | An update on amine oxidase inhibitors: Multifaceted drugs |
000148 | Russell C. Callaghan [Canada] ; James K. Cunningham [États-Unis] ; Jenna Sykes [Canada] ; Stephen J. Kish [Canada] | Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs |
000183 | Pierre J. Blanchet [Canada] ; Louise Normandeau [Canada] ; Pierre H. Rompre [Canada] | Comparing three screening tools for drug-induced parkinsonism in patients with advanced schizophrenia: A pilot study |
000287 | Sara Kost [Canada] ; CHAO SUN [Canada] ; WEI XIONG [Canada] ; Kathryn Graham [Canada] ; Carol E. Cass [Canada] ; James D. Young [Canada] ; Benedict C. Albensi [Canada] ; Fiona E. Parkinson [Canada] | Behavioral effects of elevated expression of human equilibrative nucleoside transporter 1 in mice |
000398 | Andrew R. Brown [Canada] ; BIN HU [Canada] ; Bryan Kolb [Canada] ; G. Campbell Teskey [Canada] | Acoustic tone or medial geniculate stimulation cue training in the rat is associated with neocortical neuroplasticity and reduced akinesia under haloperidol challenge |
000432 | Pierre-Luc Tremblay [Canada] ; Marc-Andre Bedard [Canada] ; Maxime Levesque [Canada] ; Mark Chebli [Canada] ; Maxime Parent [Canada] ; Richard Courtemanche [Canada] ; Pierre J. Blanchet [Canada] | Motor sequence learning in primate : Role of the D2 receptor in movement chunking during consolidation |
000476 | Jennifer R. St. Onge [Canada] ; Stan B. Floresco [Canada] | Dopaminergic Modulation of Risk-Based Decision Making |
000594 | Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
000611 | Michelle R. Ciucci [États-Unis] ; Sean T. Ma [États-Unis] ; Cynthia Fox [États-Unis] ; Jacqueline R. Kane [États-Unis] ; Lorraine O. Ramig [États-Unis] ; Timothy Schallert [États-Unis] | Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol : A preliminary study |
000675 | Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
000734 | Andrew R. Willan [Canada] ; Ron Goeree [Canada] ; Eleanor M. Pullenayegum [Canada] ; Christopher Mcburney [États-Unis] ; Gordon Blackhouse [Canada] | Economic evaluation of rivastigmine in patients with parkinson's disease dementia |
000785 | Guy Chouinard [Canada] ; Howard C. Margolese [Canada] | Manual for the Extrapyramidal Symptom Rating Scale (ESRS) |
000848 | Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Albeao Albanese [Italie] ; E. Jane Byrne [Royaume-Uni] ; Günther Deuschl [Allemagne] ; Peter P. De Deyn [Belgique] ; Franck Durif [France] ; Jaime Kulisevsky [Espagne] ; Teus Van Laar [Pays-Bas] ; Andrew Lees [Royaume-Uni] ; Werner Poewe [Autriche] ; Alain Robillard [Canada] ; Mario M. Rosa [Portugal] ; Erik Wolters [Pays-Bas] ; Peter Quarg [Suisse] ; Sibel Tekin [États-Unis] ; Roger Lane [États-Unis] | Rivastigmine for dementia associated with Parkinson's disease |
000871 | Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
000984 | Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
000993 | Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie] | Role of serotonin2C receptors in the control of brain dopaminergic function |
000B32 | Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
000B36 | Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
000B58 | Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
000D51 | L. Thorpe [Canada] | The treatment of psychotic disorders in late life |
000E13 | P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
000E43 | AGDU'L-MISSAGH GHADIRIAN [Canada] ; L. Annable ; M.-C. Belanger ; G. Chouinard | A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients |
000E50 | A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
000E72 | P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
000F49 | R. W. Lam [Canada] | Chronic schizophrenia and idiopathic Parkinson's disease |
001074 | E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
001100 | E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
![]() | This area was generated with Dilib version V0.6.29. | ![]() |